iBio receives patent approval for its iBio Modulator system
The patent allows iBio proprietary rights over its iBioModulator system, which creates modified carrier molecules from antigens or target proteins. The molecules are intended for use in the production of high-performance vaccine candidates that target difficult diseases. The system was developed by scientists at the Fraunhofer U.S.A. Center for Molecular Biotechnology, an iBio partner.
The special molecules have shown in testing to drastically change the body's immune response to a vaccine by strengthening the initial immune response to a vaccine antigen and extending the duration of that response. This method allows for fewer doses of a vaccine to achieve the same level of protection against a particular disease. This will reduce the overall cost of immunizations, while expanding the served area.
iBio is a company that specializes in the production of technology to aid biopharmaceutical production. In addition to its iBioModulator, iBio also has an application called iBioLaunch, which extracts plant proteins for use in biopharmaceutical production.